Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease | Zendy

Faı̈ez Zannad | Zendy; Stefan D. Anker | Zendy; William M. Byra | Zendy; John G.F. Cleland | Zendy; Min Fu | Zendy; Mihai Gheorghiade | Zendy; Carolyn S.P. Lam | Zendy; Mandeep R. Mehra | Zendy; James D. Neaton | Zendy; Christopher C. Nessel | Zendy; Theodore E. Spiro | Zendy; Dirk J. van Veldhuisen | Zendy; Barry Greenberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Author(s) -

Faı̈ez Zannad,

Stefan D. Anker,

William M. Byra,

John G.F. Cleland,

Min Fu,

Mihai Gheorghiade,

Carolyn S.P. Lam,

Mandeep R. Mehra,

James D. Neaton,

Christopher C. Nessel,

Theodore E. Spiro,

Dirk J. van Veldhuisen,

Barry Greenberg

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1808848

Subject(s) - rivaroxaban , heart failure , medicine , cardiology , sinus rhythm , coronary artery disease , thrombin , atrial fibrillation , warfarin , platelet

Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with worsening chronic heart failure and underlying coronary artery disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research